Hepatitis B testing is generally recommended before starting long-term systemic steroid treatment, especially when prednisone-equivalent doses are moderate or high for four weeks or longer. Steroids can weaken immune control and allow a current or past hepatitis B infection to become active again. A blood test panel checks for current infection, past infection, and vaccine protection. The results help clinicians decide whether monitoring or antiviral medicine is needed.
Why is hepatitis B screening important before long-term steroid use?
Corticosteroids, commonly called steroids, are medicines used to reduce inflammation and control immune system activity. They are prescribed for conditions such as asthma, autoimmune diseases, inflammatory disorders, and certain other medical conditions. When treatment involves sustained systemic immunosuppression, an existing hepatitis B virus (HBV) infection can become active again.
This process is called hepatitis B reactivation. It can occur in people who have a current hepatitis B infection and in some people whose previous infection appeared to have resolved. Reactivation may cause a rise in the amount of virus in the blood, inflammation of the liver, and, in some cases, serious liver complications. The University of Washington's Hepatitis B Online resource explains that immunosuppressive treatment is a common trigger and that risk depends on both hepatitis B test results and the medicines used.
Hepatitis B can remain undetected because many people have no noticeable symptoms. A person may also have normal liver enzyme results despite having an infection or a history of infection relevant to future immunosuppressive treatment. Screening helps identify these situations before steroids are started, allowing the prescribing clinician to plan appropriate monitoring or preventive treatment.
Who needs hepatitis B testing before starting steroids?
Testing is particularly important before a planned course of systemic steroids that is expected to continue for several weeks or longer. The American Association for the Study of Liver Diseases (AASLD) recommends hepatitis B surface antigen and core antibody testing before immunosuppressive, cytotoxic, or immunomodulatory treatment. Current guidance also supports using a three-test hepatitis B panel before immunosuppression.
Screening is relevant even if someone does not know of any previous exposure to hepatitis B. It is especially important when a person has a history of hepatitis B, has lived in or comes from a region where the infection is more common, has a household or sexual contact with hepatitis B, or has never had hepatitis B screening. However, a known risk factor is not required for testing to be useful before long-term immunosuppressive treatment.
When possible, blood should be collected before the first steroid dose. This gives the clinical team time to interpret the results and arrange preventive care when needed. If steroid treatment is urgent, the prescriber can coordinate screening and any necessary preventive measures with the treatment schedule rather than automatically delaying essential care.
How do steroid dose and treatment duration affect the need for testing?
The risk of hepatitis B reactivation depends partly on how much steroid is taken, how long it is used, whether the person has current or past hepatitis B infection, and whether other immune-suppressing medicines are prescribed at the same time.
The 2025 American Gastroenterological Association (AGA) guideline on preventing hepatitis B reactivation distinguishes steroid doses by their daily prednisone equivalent:
- Low dose: Less than 10 mg of prednisone per day.
- Moderate dose: 10–20 mg of prednisone per day.
- High dose: More than 20 mg of prednisone per day.
These categories help clinicians estimate reactivation risk when combined with treatment duration and hepatitis B test results. Moderate- or high-dose systemic corticosteroids taken for four weeks or longer are an important risk situation. In people with current hepatitis B infection, this treatment pattern can carry a substantial reactivation risk. Risk classifications differ for people whose hepatitis B surface antigen is negative but whose core antibody indicates previous infection.
Brief steroid courses and injections into a joint generally have a lower hepatitis B reactivation risk than prolonged systemic treatment. Low-dose treatment can also carry a lower risk in some circumstances. These differences may affect follow-up and preventive treatment decisions, but they should not be used alone to decide whether an individual needs screening. Other medicines, previous hepatitis B results, and the reason for treatment also matter.
Which hepatitis B blood tests are needed before steroid therapy?
The usual initial screening approach is a hepatitis B triple panel. It includes three blood tests that help distinguish current infection, previous infection, and vaccine-related immunity. The US Centers for Disease Control and Prevention (CDC) recommends this three-test panel for initial hepatitis B screening in adults and explains how the results help guide further evaluation.
Hepatitis B surface antigen (HBsAg)
This test looks for a protein on the surface of the hepatitis B virus. A positive result usually indicates a current infection, although additional testing is needed to establish its status and guide management. A clinician may order hepatitis B virus DNA testing and liver blood tests to assess viral activity and its effects on the liver.
Hepatitis B core antibody (total anti-HBc)
This antibody usually indicates that the person has been exposed to hepatitis B at some point. It may be present in both current and resolved infections. It is particularly important before immunosuppressive treatment because people who are negative for HBsAg but positive for anti-HBc can still be at risk of reactivation. Hepatitis B vaccination alone does not produce a positive core antibody result.
Hepatitis B surface antibody (anti-HBs)
This test helps show whether a person has immunity to hepatitis B. It can become positive after vaccination or following recovery from an infection. Its meaning depends on the other two test results, so it should not be interpreted on its own when assessing reactivation risk before steroids.
In the United States, the CDC recommends one-time routine screening for adults aged 18 years and older. Younger people may also need hepatitis B testing before immunosuppressive therapy, depending on their medical history and planned treatment. Local screening recommendations may differ by country.
What happens if hepatitis B testing is positive?
A positive or unexpected result does not automatically mean that steroid treatment cannot be given. It means the clinical team needs to establish what the result indicates and decide how to reduce the risk of complications. According to MedlinePlus, abnormal hepatitis testing may indicate a current or past infection, and additional blood tests can be needed to clarify the findings.
If HBsAg is positive, the clinician will generally assess the infection further, including the amount of virus in the blood and relevant liver tests. Depending on the findings and planned steroid regimen, antiviral treatment may be recommended before immunosuppression begins or no later than its start. A clinician experienced in hepatitis B management may help determine the most appropriate approach.
If HBsAg is negative but anti-HBc is positive, the results may indicate a previous infection. This does not always require preventive antiviral medicine. Depending on the planned steroid dose and duration, other immunosuppressive medicines, and the person's clinical circumstances, the care team may recommend preventive antiviral treatment or regular monitoring with blood tests.
Monitoring may include liver enzyme measurements, hepatitis B surface antigen testing, and HBV DNA testing at intervals chosen by the treating clinician. Follow-up can remain important after steroids are reduced or stopped because reactivation may occur after immunosuppressive treatment has ended. The monitoring schedule and duration depend on the medicines used and the person's hepatitis B status.
What should you discuss with your doctor before long-term steroids?
Before starting treatment, tell your prescribing clinician whether you have ever been diagnosed with hepatitis B, had a previous positive hepatitis B test, received treatment for the infection, or had a close contact with someone who has hepatitis B. Mention any previous hepatitis B test results and any other medicines that suppress the immune system.
Ask whether a hepatitis B triple panel is appropriate, whether any additional blood tests are needed, and whether the planned dose and duration of steroids call for preventive antiviral treatment or ongoing monitoring. If you have already started steroids and have not been screened, discuss testing with your clinician promptly. Do not stop prescribed steroids or change the dose on your own; abrupt changes can be unsafe for some treatment plans.